| Drug General Information |
| Drug ID |
D0T0BY
|
| Former ID |
DNC004793
|
| Drug Name |
2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C16H15N3O2
|
| Canonical SMILES |
C1COCCN1C2=CC(=O)N3C=CC4=CC=CC=C4C3=N2
|
| InChI |
1S/C16H15N3O2/c20-15-11-14(18-7-9-21-10-8-18)17-16-13-4-2-1-3-12(13)5-6-19(15)16/h1-6,11H,7-10H2
|
| InChIKey |
BVRDQVRQVGRNHG-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
DNA-dependent protein kinase catalytic subunit |
Target Info |
Inhibitor |
[1]
|
|---|
| Serine/threonine-protein kinase mTOR |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Non-homologous end-joining
|
|
Cell cyclehsa04012:ErbB signaling pathway
|
|
HIF-1 signaling pathway
|
|
mTOR signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Insulin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Type II diabetes mellitus
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Acute myeloid leukemia
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancer
|
|
NetPath Pathway
|
IL1 Signaling Pathway
|
|
PANTHER Pathway
|
Hypoxia response via HIF activation
|
|
Interleukin signaling pathway
|
|
Pathway Interaction Database
|
DNA-PK pathway in nonhomologous end joining
|
|
Coregulation of Androgen receptor activity
|
|
Class I PI3K signaling events mediated by Akt
|
|
BARD1 signaling eventsil4_2pathway:IL4-mediated signaling events
|
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
IL12-mediated signaling events
|
|
CDC42 signaling events
|
|
LKB1 signaling events
|
|
Regulation of Telomerase
|
|
mTOR signaling pathway
|
|
CXCR4-mediated signaling events
|
|
EGFR-dependent Endothelin signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
IFN-gamma pathway
|
|
ErbB1 downstream signaling
|
|
ErbB2/ErbB3 signaling events
|
|
CXCR3-mediated signaling events
|
|
PathWhiz Pathway
|
Leucine Stimulation on Insulin Signaling
|
|
Reactome
|
Nonhomologous End-Joining (NHEJ)R-HSA-1257604:PIP3 activates AKT signaling
|
|
Macroautophagy
|
|
mTORC1-mediated signalling
|
|
HSF1-dependent transactivation
|
|
CD28 dependent PI3K/Akt signaling
|
|
VEGFR2 mediated vascular permeability
|
|
TP53 Regulates Metabolic Genes
|
|
Constitutive Signaling by AKT1 E17K in Cancer
|
|
WikiPathways
|
DNA Damage Response
|
|
Non-homologous end joining
|
|
FAS pathway and Stress induction of HSP regulation
|
|
Cytosolic sensors of pathogen-associated DNA
|
|
Retinoblastoma (RB) in Cancer
|
|
Prostate Cancer
|
|
Double-Strand Break Repair
|
|
Cell Cycle
|
|
miRNA Regulation of DNA Damage ResponseWP673:ErbB Signaling Pathway
|
|
Senescence and Autophagy in Cancer
|
|
Interferon type I signaling pathways
|
|
Insulin Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
Wnt Signaling Pathway Netpath
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
Cardiac Hypertrophic Response
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
PIP3 activates AKT signaling
|
|
Polycystic Kidney Disease Pathway
|
|
Alpha 6 Beta 4 signaling pathway
|
|
BDNF signaling pathway
|
|
Oncostatin M Signaling Pathway
|
|
TSLP Signaling Pathway
|
|
FSH signaling pathway
|
|
Leptin signaling pathway
|
|
TSH signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
SREBF and miR33 in cholesterol and lipid homeostasis
|
|
Integrated Breast Cancer Pathway
|
|
SREBP signalling
|
|
Signaling by Insulin receptor
|
|
Costimulation by the CD28 family
|
|
Type II diabetes mellitus
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
TOR Signaling
|
|
AMPK Signaling
|
| References |
| REF 1 | J Med Chem. 2005 Jan 27;48(2):569-85.Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and radiosensitization of a human tumor cell line in vitro. |
|---|
